SeaStar Medical Holding Corporation (ICUCW) Aktienanalyse

Unternehmensübersicht

SeaStar Medical Holding Corporation operates as a commercial-stage medical device company focused on the development of a proprietary platform therapy designed to mitigate the consequences of hyperinflammation on vital organs within the United States. The firm offers the selective cytopheretic device (SCD), which functions as a disease-modifying device intended to address specific pathological conditions. Although the specific sector and industry classifications are not publicly disclosed in the available data, the company's operational focus remains firmly within the medical technology domain, targeting therapies that alter the course of disease progression. In terms of scale, the company reports a total market cap and price-to-sales valuation metrics that are currently not available, while its annual revenue stands at $1.23 million and it employs a workforce of 17 individuals. The combination of a relatively small employee base, modest annual revenue, and unavailable market capitalization figures suggests that SeaStar Medical operates as a specialized entity rather than a broad-market leader, indicating a position that relies heavily on future commercialization success and proprietary technology validation to achieve significant scale.

Finanzielle Gesundheit

The company generated revenue of $1.23 million over the trailing twelve months, yet this top-line performance is contrasted sharply by a net income of -$12,150,000, revealing a cost structure where expenses substantially outweigh earnings. This significant disparity between positive revenue and substantial negative net income indicates that the company is in a heavy investment or loss-making phase typical of early-stage commercialization. While the EBITDA figure is not available, the free cash flow stands at -$9,391,750, which signifies a net outflow of cash and limited financial flexibility for capital expenditures or acquisitions without additional funding. The gross margin is reported at 95.7%, indicating highly efficient production costs relative to revenue, yet the operating margin is -718.1% and the profit margin is 0.0%, reflecting intense overhead burdens or R&D expenditures that have not yet been offset by profitability. The balance sheet shows $11.98 million in cash against $525,000 in debt, resulting in a debt-to-equity ratio of 5.04, which implies a highly leveraged capital structure relative to equity, despite the substantial cash reserve. The current ratio of 3.63 demonstrates strong short-term liquidity, suggesting the company can easily cover its current liabilities with its current assets. Furthermore, the return on equity is -295.2% and the return on assets is -80.9%, metrics that reveal management effectiveness is currently measured by capital preservation and product development rather than profit generation from existing assets.

Bewertungsanalyse

The trailing P/E ratio and forward P/E ratio are both not available, which implies that traditional earnings-based valuation multiples cannot be applied to assess the expected earnings trajectory given the negative net income position. The price-to-book ratio is 0.01, indicating that the market values the company's equity at a fraction of its book value, suggesting a deep discount or a lack of recognized tangible asset backing in the current market price. The price-to-sales ratio and EV/EBITDA are also not available, meaning alternative valuation metrics that might provide insight into the company's revenue quality or enterprise value relative to earnings are currently indeterminate. The stock's 52-week high and 52-week low are both recorded at $0.03, meaning the current trading price sits at the upper bound of this extremely narrow range, showing no price movement over the past year. The beta value is -1.19, a negative figure that suggests the stock price moves inversely to the broader market and exhibits volatility patterns distinct from standard equity instruments. These valuation characteristics highlight the high risk profile associated with a company trading at a single price point with no earnings history or traditional valuation support.

Growth & Income

The revenue growth year-over-year is 526.9%, while earnings growth is not available due to the negative net income, implying that top-line expansion is occurring without corresponding profit realization. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, indicating that it retains all earnings to fund operations, R&D, and growth initiatives rather than returning capital to shareholders. The absence of a dividend yield suggests that the company reinvests its limited cash flows and available reserves directly into the development of the selective cytopheretic device and the expansion of its proprietary platform therapy. The overall growth and income profile is defined by explosive top-line revenue expansion coupled with significant losses, a pattern common among commercial-stage medical device firms that have not yet achieved break-even profitability.